Group 1: Company Overview - Fulejia is a professional skin care product company focused on R&D, production, and sales of medical devices and functional skin care products, with a multi-channel sales strategy that includes both online and offline platforms [2][3]. - The company has established a comprehensive market reach through major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline channels including specialty cosmetics stores, large supermarkets, chain pharmacies, beauty institutions, and medical facilities [2]. Group 2: Product Registration and R&D - Fulejia has obtained 4 Class II medical device registrations, including products such as medical sodium hyaluronate repair patches and medical recombinant type III humanized collagen patches [3]. - The company has two R&D centers located in Shanghai and Harbin, focusing on raw material development and medical device product R&D, respectively [3]. - In 2025, Fulejia registered 48 cosmetic products, covering various forms such as water, lotion, cream, and essence [4]. Group 3: Clinical Trials and Product Development - The clinical trial for the recombinant type III humanized collagen freeze-dried fiber project has been completed, and the company is preparing the clinical trial summary report for registration submission [4]. - In 2025, the company completed the registration of two new raw materials, which will be developed into products to enhance the product matrix [3]. Group 4: Channel Optimization and Management - The company is optimizing its offline channels, focusing on sales channel and retail terminal improvements, with financial feedback showing some lag [4][5]. - Future strategies include strengthening partnerships with service-oriented distributors and implementing a dual approach of "strong supervision + strong optimization" to enhance market control and stabilize pricing [5]. Group 5: Management and Shareholding - Currently, there is no intention for the company's directors and senior management to reduce their holdings [5].

Core Viewpoint - HBN, a rising skincare brand in China, is preparing for an IPO on the Hong Kong Stock Exchange, aiming to capitalize on the growing trend of domestic consumer brands going public [1][2]. Company Overview - HBN, founded in 2019, focuses on effective skincare products, particularly promoting the "Morning C, Evening A" concept, which emphasizes using vitamin C in the morning and retinol at night [2][4]. - The brand has quickly gained popularity, becoming one of the youngest brands in the top ten domestic skincare market, achieving significant sales growth within a short period [1][4]. Financial Performance - HBN's revenue reached approximately 19.48 billion RMB in 2023, with projections of 20.8 billion RMB in 2024 and 15.14 billion RMB for the first three quarters of 2025 [8]. - The net profit for the same periods was 38.8 million RMB, 129 million RMB, and 145 million RMB, indicating a substantial increase in net profit margin from 1.9% to 9.6% [8]. - The brand's average repurchase rates on platforms like Tmall and Douyin are around 35.4% and 44.0%, respectively, with over 4.6 million cumulative repurchase users [8]. Product and Market Position - HBN's product lines include anti-aging and daily skincare products, with prices ranging from 129 RMB to 689 RMB [6]. - The brand is ranked fourth among domestic mid-to-high-end skincare brands and is the largest domestic brand in the improvement skincare segment [8]. Business Structure and Risks - HBN's revenue is heavily reliant on a few key products, which accounted for nearly 40% of sales, raising concerns about business sustainability [9]. - The company has a high concentration of online sales, with online revenue accounting for over 95% in recent years, indicating limited diversification in sales channels [9][10]. Investment and Shareholding - Prior to the IPO, HBN's founders held a combined 76.19% voting power, with significant external investment from Meitu, which holds 23.81% of the shares [5]. - The company recently declared a cash dividend of 100 million RMB, with a portion already paid out, benefiting the founders significantly [5]. Industry Context - The trend of consumer brands going public in Hong Kong is accelerating, with numerous companies filing for IPOs, indicating a competitive environment for HBN [12][13]. - The Hong Kong Stock Exchange is experiencing a surge in IPO applications, with over 350 companies in the queue, highlighting the urgency for HBN to finalize its listing [16].

Core Viewpoint - HBN, a rising skincare brand in China, is preparing for an IPO on the Hong Kong Stock Exchange, aiming to capitalize on the current trend of domestic consumer brands going public [4][5]. Company Overview - HBN's parent company, Shenzhen Hujia Technology (Group) Co., Ltd., has submitted its IPO application, with Morgan Stanley and CICC as joint sponsors [4]. - Founded by a couple from Guangdong, HBN has quickly gained popularity in the skincare market, particularly with its "Morning C, Evening A" skincare philosophy [5][7]. - The brand has achieved significant revenue growth, entering the 2 billion to 4 billion RMB revenue tier within four years of its establishment [7][12]. Financial Performance - HBN's revenue for the first three quarters of 2023, 2024, and 2025 was 1.948 billion, 2.082 billion, and 1.373 billion RMB respectively, with net profits of 38.8 million, 129 million, and 145 million RMB, showing a net profit margin increase from 1.9% to 9.6% [12][14]. - The brand's product lines include both improvement-type and maintenance-type skincare products, with the former accounting for approximately 80% of revenue [12][13]. Market Position - HBN ranks fourth among domestic mid-to-high-end skincare brands in China, and it is the largest domestic brand in the improvement-type skincare market [12]. - The brand's average repurchase rates on platforms like Tmall and Douyin are approximately 35.4% and 44.0%, respectively, indicating strong customer loyalty [12]. Business Structure and Risks - HBN's revenue is heavily reliant on a few key products, which accounted for nearly 40% of sales, raising concerns about business vulnerability [13]. - The company's sales channels are predominantly online, with online revenue accounting for over 95% in recent years, while offline revenue remains below 1 billion RMB [13][14]. - Marketing expenses are high, with over 50% of revenue spent on marketing, while R&D investment has decreased, leading to questions about the sustainability of its competitive edge [14][15]. Industry Context - The current IPO climate in Hong Kong is competitive, with many consumer brands rushing to list, reflecting a broader trend of domestic companies seeking capital through public offerings [16][18]. - The Hong Kong Stock Exchange has over 350 companies in the IPO pipeline, indicating a robust interest in market entry despite regulatory challenges [18].

Group 1 - The Beijing Cultural and Tourism Bureau has selected 26 "Beijing Gifts" for the upcoming Lunar New Year, with the Plant Doctor's Dendrobium Orchid series recognized as a top choice in personal care and wellness [1] - The Dendrobium plant, historically known as "immortal grass," contains active ingredients such as polysaccharides and polyphenols, offering multiple skincare benefits including anti-aging and moisturizing [3] - The Plant Doctor has innovatively transformed large molecular Dendrobium polysaccharides into smaller, more absorbable Dendrobium oligosaccharides, achieving a breakthrough in the application of active ingredients and securing European patent authorization [3] Group 2 - The Dendrobium Orchid series has shown strong market performance, with annual sales exceeding 5.8 billion yuan, including over 4.26 million units sold of the Dendrobium Orchid Firming Eye Cream and 220 million units of the Dendrobium Orchid Fresh Skin Mask [3] - Euromonitor International has recognized the Plant Doctor as the leading brand in Dendrobium skincare products for three consecutive years, affirming its market position [4] - The Plant Doctor represents a blend of Eastern wisdom and modern technology, showcasing Chinese brands and ingredients on international platforms, such as the 2025 China International Fair for Trade in Services [5] Group 3 - Since its establishment in 1994, the Plant Doctor has focused on transforming traditional Chinese plant resources into internationally competitive skincare products, emphasizing a commitment to nature and science [7] - The inclusion of the Dendrobium Orchid in the "Beijing Gifts" signifies not only product recognition but also a step forward in cultural confidence and technological self-reliance for Chinese brands [7] - The Plant Doctor operates over 5,000 single-brand stores globally, serving more than 29 million members, and aims to promote the innovation and breakthroughs of Chinese brands in the skincare sector [7]

又一网红品牌要IPO了。 近日，国货网红护肤品牌HBN的主体公司深圳护家科技（集团）股份有限公司（简称：护家科技）递表港交所，冲击"中国真功效护肤第一股"。 作为中国领先的皮肤学级护肤品牌，护家科技是最早提出"早C晚A"护肤理念的国产护肤品牌之一。 根据灼识咨询，按2024年护肤品零售额计，护家科技已发展为中国护肤品市场前十大国产品牌中最年轻的品牌，亦是中国改善型护肤品市场中最大的皮肤 学级国产护肤品牌。 而它的故事，还得从80后掌舵者姚哲男的跨界创业谈起。 姚哲男是安徽人，早在17岁时便奔赴英国留学，并在2006年与2008年先后获得英国中央兰开夏大学的平面设计学士学位与动画学硕士学位。 回国后，2009年至2023年，姚哲男便担任起了深圳大学的数字媒体艺术系讲师以及研究生导师。 而这期间，他亦创办了护家科技，并由此开始了两段创业旅程。 在护家科技创业的上半场，注册成立时，本公司是由深圳市护你全家科技有限公司全资拥有，后者随后更名为深圳市护家生物科技有限公司(于2025年10 月13日被注销)，主要从事女性护理用品销售业务。 根据天眼查显示，护家生物旗下是卫生巾品牌护你妹，于2014年至2018年间融过4轮 ...

Group 1 - Ugreen Technology has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International as its sole sponsor. The company is a consumer electronics brand focusing on charging, smart office, smart audio-visual, and smart storage products, aiming to become the global leader in the tech consumer electronics market by shipment volume by 2025 [1] - JD Group's European online retail platform, Joybuy, is set to launch in March 2023, leveraging JD's supply chain and logistics capabilities to achieve same-day and next-day delivery in multiple cities across the UK during its trial operation [2] - China Merchants Shekou's contract sales for the year ending December 31, 2025, amounted to approximately RMB 32.308 billion, reflecting a significant year-on-year decrease of 23.91%. The average selling price was approximately RMB 24,918 per square meter [3] Group 2 - Citi has initiated coverage on Lin Qingxuan with an "Outperform" rating, highlighting the company's expansion into the high-end anti-aging and skin-tightening market, which is expected to grow at a compound annual growth rate of 18.9% from 2024 to 2029. The firm forecasts Lin Qingxuan's sales and adjusted net profit to grow at compound annual rates of 42% and 49%, respectively, from 2025 to 2027, with a target price of HKD 128.5 [4]

Core Viewpoint - The report from Citi initiates coverage on Lin Qingxuan (02657) with a "Outperform" rating, highlighting the company's expansion into the high-end anti-aging and skin-tightening market, which is expected to grow faster than the overall skincare market [1] Industry Summary - The high-end anti-aging and skin-tightening market is projected to have a compound annual growth rate (CAGR) of 18.9% from 2024 to 2029, indicating significant growth potential [1] Company Summary - Lin Qingxuan is expected to leverage the rapid growth opportunities in the skincare sector through an integrated online and offline model to enhance brand awareness [1] - Sales and adjusted net profit for Lin Qingxuan are forecasted to achieve a CAGR of 42% and 49% respectively from 2025 to 2027 [1] - The target price for Lin Qingxuan is set at HKD 128.5, corresponding to a projected price-to-earnings ratio of approximately 19 times for the next 12 months [1]

Group 1 - The core viewpoint of the report is that Lin Qingxuan (02657) is expected to outperform the market, with a focus on the high-end anti-aging and skin-tightening segment, which is projected to grow faster than the overall skincare market [1] - The expected compound annual growth rate (CAGR) for the high-end anti-aging segment from 2024 to 2029 is 18.9%, indicating significant growth opportunities for the company [1] - The company is anticipated to enhance brand awareness through an integrated online and offline model, capitalizing on the rapid growth in the skincare market [1] Group 2 - The forecasted CAGR for Lin Qingxuan's sales and adjusted net profit from 2025 to 2027 is 42% and 49% respectively, showcasing strong financial growth potential [1] - The target price for Lin Qingxuan is set at HKD 128.5, which corresponds to a projected price-to-earnings ratio of approximately 19 times for the next 12 months [1]

IPO Dynamics - Muyuan Foods plans to launch its Hong Kong IPO as early as January 29, aiming to raise up to $1.5 billion (approximately HKD 11.7 billion) and is expected to list on February 6 [3] - The funds raised will be used for overseas expansion, smart farming R&D, and debt repayment, potentially creating an "A+H" dual financing platform to strengthen capital during the pig cycle downturn [3] Acquisitions & Sales - JBB Builders is in discussions to acquire 100% equity of Chengdu Jianfu Convenience Store Management Co., which operates 65 direct stores and 30 franchised stores, aiming to enter the rapidly growing Chinese retail market [5] - Unilever has signed an agreement to sell its home care business in Colombia and Ecuador to Alicorp, which includes established local brands like Fab and 3D [8] - General Mills announced the sale of its Muir Glen organic tomato brand to Violet Foods, allowing General Mills to focus on core brands like Cheerios and Progresso [12] - Vitabiotics, a UK vitamin company, is attracting bids from private equity firms including Bain Capital and Blackstone, with a potential valuation of around £900 million (approximately RMB 8.6 billion) [15] Corporate Restructuring - MTG Corporation announced the dissolution of its wholly-owned subsidiary in Shanghai, which has been operating since 2013 and responsible for sales in the Chinese market, due to continuous losses [18][19] - On (昂跑) appointed Frank Sluis as the new CFO, expected to drive sales growth of at least 34% year-on-year for the fiscal year 2025 [21] - BVLGARI appointed Domenico Giampà as the director of its fragrance business, focusing on commercial strategy and growth in high-end fragrance segments [24] - L'OCCITANE appointed Mark Edington as the general manager for travel retail in EMEA and the Americas, leveraging his extensive experience to boost travel retail performance [27] - A2 Milk Company expanded the responsibilities of its Greater China CEO, allowing for better local management of market strategies [30]

Group 1 - The core viewpoint of the report is that Lin Qingxuan has been rated "Outperform" by Credit Lyonnais, highlighting its expansion into the high-end anti-aging and skin-tightening market [1] - The industry data indicates that the growth rate of this segment is expected to exceed that of the overall skincare market, with a projected compound annual growth rate (CAGR) of 18.9% from 2024 to 2029 [1] - The company is believed to be well-positioned to capitalize on this rapid growth opportunity by enhancing brand awareness through an integrated online and offline model [1] Group 2 - Credit Lyonnais forecasts that Lin Qingxuan's sales and adjusted net profit will achieve a CAGR of 42% and 49%, respectively, from 2025 to 2027 [1] - The target price for Lin Qingxuan is set at HKD 128.5, which corresponds to a projected price-to-earnings ratio of approximately 19 times for the next 12 months [1]